Novartis Bags Chong Kun Dang’s HDAC6 Inhibitor In $1.3bn Deal

Potential In Cardiovascular Indications

 
• By Jung Won Shin
  
Biggest Deal
Korea's Chong Kun Dang strikes its biggest ever licensing deal • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip